Pilot Study of 18F-FLT PET

Not Applicable

Terminated

• Conditions: Lung Cancer; Esophageal Cancer; Head and Neck Cancer; CNS Brain Metastasis; Prostate Cancer

• Registration Number: NCT00585741
• Lead Sponsor: University of Wisconsin, Madison

Brief Summary

Fractionated radiotherapy induces an observable change in the proliferative activity as assessed by pre-treatment and early-treatment 18F-FLT PET imaging. This study is designed to investigate 18F-FLT as a PET imaging agent for predicting treatment effectiveness in several tumors and will serve as a pilot study to a planned PO1 submission

Detailed Description

Not available

Study Timeline

• Study Start: 2006-12
• Study First Submitted: 2007-12-21
• Study First Submitted QC: 2007-12-21
• Study First Posted: 2008-01-03
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2012-02
• Last Update Submitted: 2012-02-22
• Last Update Posted: 2012-02-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 15

Inclusion Criteria

• Able to tolerate a PET/CT scan
• Age of 18 or older
• signed informed consent
• being considered for radiotherapy for treatment of CNS mets, Head and neck cancer, lung cancer, prostate cancer or esophageal cancer

Exclusion Criteria

• Prior XRT to site being studied
• severe claustrophobia or inability to tolerate PET/CT
• unable to provide written consent
• pregnant or breastfeeding women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To test whether the cellular response to fractionated radiotherapy leads to observable global change in the uptake of 18F-FLT as assessed by PET imaging	end of study

Secondary Outcome Measures

Name	Time	Method
To assess the technical and logistic feasibility of 18F-FLT scans in a population of cancer patients	end of study

Trial Locations

Locations (1)

University of Wisconsin Hospital and clinis; 🇺🇸 Madison, Wisconsin, United States